Post Herpetic Neuralgia Treatment Market - Major Factors Driving the Industry

Post herpetic neuralgia (PHN) is neuropathic pain that generally arises due to injury. In many cases, the injury to the peripheral nerves is triggered by the recurrence of a virus named varicella zoster. The virus causes herpes zoster or shingles. Neuralgia usually occurs in areas with a single sensory nerve. Post herpetic neuralgia may last for approximately 85 days. A person may also suffer from various other conditions in combination with PHN. For example, itching, abnormal sensation, pain due to gentle touch, hyperalgesia, etc.

Report Overview @ https://www.transparencymarketresearch.com/post-herpetic-neuralgia-treatment-market.html

The global post herpetic neuralgia treatment market is expected to expand rapidly in the coming years. The post herpetic neuralgia treatment market is mainly driven by an increase in the prevalence of post herpetic neuralgia and rise in the ageing population. PHN usually affects adults aged 50 and older whose immunity is weaker compared to that of younger people. According to research findings by the CDC and World Health Organization (WHO), among individuals experiencing shingles, age is a major factor for the periodical development of PHN. The findings also suggest that the risk of PHN slowly increases with age, especially for persons aged above 50 years.

Roughly 80%-85% of PHN cases occur in patients aged more than 50 years. A rise in the geriatric population is expected to increase screening rates for diseases. For example, according to research findings by the Centers for Diseases Control and Prevention (CDC), cases of post herpetic neuralgia (PHN) are increasing rapidly among the adult population in the U.S. The prevalence rate is approximately 4 to 5 per 1000 individuals amongst the U.S. population. The incidence rate is roughly around 3.2 to 4.2 per 1000 individuals per year.

Get a Glimpse of the In-Depth Analysis through our Comprehensive "Post Herpetic Neuralgia Treatment Market" Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61539

Furthermore, research estimates that 1 million cases of post herpetic neuralgia are recorded annually. This leads to unmet needs in different sections of the society. The development of health care infrastructure in developed as well as developing countries and government initiatives to spread awareness regarding post herpetic neuralgia treatment products are expected to drive the market. An important factor that is likely to drive the market is advancements in treatment techniques for post herpetic neuralgia.

For example, the development of idocaine and capsaicin has gained traction in the herpetic neuralgia treatment market. However, poor efficiency and efficacy of some drugs and highcost of the drugs are expected to hamper the global post herpetic neuralgia treatment market. Additionally, concerns over opioid usage and increase in mortality due to over dose are some of the other factors that may hinder the growth of the market.

The global post herpetic neuralgia treatment market can be segmented based on treatment type, distribution channel, and region. In terms of treatment type, the post herpetic neuralgia treatment market can be classified into patches, drugs, and opioids. The patches segment can be sub-divided into capsaicin skin patches and lidocaine skin patches. Based on distribution channel, the post herpetic neuralgia treatment market can be divided into hospital pharmacies, drug stores, retail pharmacies, and others.

In terms of region, the global post herpetic neuralgia treatment market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is expected to dominate the market in the coming years. This is due to higher purchasing power of the population, developed economy, better reimbursement policies, rise in the incidence of post herpetic neuralgia, presence of key players, and higher health care expenditure.

Pre Book "Post Herpetic Neuralgia Treatment Market" Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=61539<ype=S

For example, in 2017, the health care expenditure in the U.S. was nearly 16% of its GDP. Europe and Asia Pacific are expected to be prominent regions of the market. Factors such as an ageing population and significant investments in health care infrastructure are expected to propel the market in Asia Pacific. Presence of rapidly developing economies such as India, China, and the Philippines is also expected to boost the post herpetic neuralgia treatment market in the region.

Some of the key players operating in the global post herpetic neuralgia treatment market are Pfizer Inc, Teikoku Pharma USA, Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Endo Pharmaceuticals Inc..

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.